Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.
Randomized Controlled Trial Evaluating the Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.
University Hospital, Bordeaux
592 participants
Mar 13, 2026
INTERVENTIONAL
Conditions
Summary
The occurrence of interval cancers after colonoscopy raises the possibility of missed lesions. High- performance computer aided diagnosis (CAD) systems have been specially designed for the detection of colorectal lesions (CAD for detection is named CADe). The use of CADe improves adenoma detection in screening colonoscopy. The potential of CADe system in reducing the rate of progression to advanced polyps or interval cancer between two colonoscopies remains still uncertain.
Eligibility
Inclusion Criteria3
- Patients over 18 years of age with indication for colonoscopy as part of a screening program, after a positive immunological (FIT) test, and/or for personal or family history of colorectal cancer and/or personal history of colonic adenomas,
- Written informed consent signed
- Patients covered by a health-care insurance.
Exclusion Criteria9
- Failed complete colonoscopy, defined by the absence of cecal intubation and/or the absence of terminal ileum cauterization
- Inadequate bowel preparation (Boston bowel preparation score \< 6, and/or least at one part of colon with score ≤ 1)
- An infiltrative tumor was diagnosed during colonoscope insertion time, not accessible to endoscopic resection and likely to require surgical management (a procedure where part of the colon may need to be removed).
- Patient under guardianship or protection
- Pregnant women
- Not fluent in French or illiterate
- Personal history of inflammatory bowel disease
- Personal history of genetic predisposition of CRC
- Personal history of colonic surgery
Interventions
Colonoscopy standard (without CADe)
colonoscopy with CADe
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07299071